logo-loader
viewSummit Therapeutics PLC

Summit Therapeutics to receive US$22mln milestone payment as final patient enrols for DMD trial

Summit hopes the trial will identify utrophin modulation as a potential disease-modifying treatment for all patients suffering Duchenne Muscular Dystrophy

picture of boy
DMD affects boys and young men

Summit Therapeutics PLC (NASDAQ:SMMT LON:SUMM) will receive a US$22mln milestone payment from Sarepta Therapeutics (NASDAQ:SRPT) after the final patient was enrolled in a dosing trial of utrophin modulator, ezutromid.

Summit hopes the trial will identify utrophin modulation as a potential disease-modifying treatment for all patients suffering Duchenne Muscular Dystrophy (DMD),  a progressive and fatal muscle wasting disease that affects 50,000 boys and young men globally.

The endpoints for PhaseOut DMD, a phase II trial of ezutromid, are muscle structure, health and function improvements.

Dosing of the last patient  triggered a US$22mln payment for Summit through its licence and collaboration agreement with Sarepta (NASDAQ:SRPT). 

David Roblin, chief operating officer and Summit’s president of R&D said: "Utrophin modulation has potential as a universal treatment option for patients with DMD, and we look forward to the 24-week data readout expected in the first quarter of 2018."

The PhaseOut DMD will monitor 40 patients at sites in the UK and the US and take 48-weeks overall to complete.

As part of the trial, each patient undergoes two biopsies, a baseline biopsy on enrolment and a second either at 24 or 48 weeks.

In the first quarter of 2018, Summit expects to report 24-week biopsy analysis from approximately 20 patients, as well as 24-week MRI and functional data from all 40 patients enrolled in the trial.

Top-line data from the complete 48-week trial is expected in the third quarter of 2018.

Shares in Summit rose by 5% to 187p.

Quick facts: Summit Therapeutics PLC

Price: - -

AIM:SUMM
Market: AIM
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln...

on 10/2/20

2 min read